NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Lymphoma, B-Cell, Lymphoma, Follicular

Countries: Germany

This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Women and men aged \>=18 years
* Previously untreated CD-20 positive follicular NHL
* Previously untreated CD-20 positive DLBCL
* Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study)
* Suitability for the therapy with MabThera SC

Exclusion Criteria:

All contraindications, interactions and incompatibilities for therapy with MabThera SC

Locations (1)

Essen, Germany